488 related articles for article (PubMed ID: 30196207)
1. Discovery of Wogonin-based PROTACs against CDK9 and capable of achieving antitumor activity.
Bian J; Ren J; Li Y; Wang J; Xu X; Feng Y; Tang H; Wang Y; Li Z
Bioorg Chem; 2018 Dec; 81():373-381. PubMed ID: 30196207
[TBL] [Abstract][Full Text] [Related]
2. Design of wogonin-inspired selective cyclin-dependent kinase 9 (CDK9) inhibitors with potent in vitro and in vivo antitumor activity.
Wang J; Li T; Zhao T; Wu T; Liu C; Ding H; Li Z; Bian J
Eur J Med Chem; 2019 Sep; 178():782-801. PubMed ID: 31238183
[TBL] [Abstract][Full Text] [Related]
3. Recent Developments in the Biology and Medicinal Chemistry of CDK9 Inhibitors: An Update.
Wu T; Qin Z; Tian Y; Wang J; Xu C; Li Z; Bian J
J Med Chem; 2020 Nov; 63(22):13228-13257. PubMed ID: 32866383
[TBL] [Abstract][Full Text] [Related]
4. Wogonin and related natural flavones are inhibitors of CDK9 that induce apoptosis in cancer cells by transcriptional suppression of Mcl-1.
Polier G; Ding J; Konkimalla BV; Eick D; Ribeiro N; Köhler R; Giaisi M; Efferth T; Desaubry L; Krammer PH; Li-Weber M
Cell Death Dis; 2011 Jul; 2(7):e182. PubMed ID: 21776020
[TBL] [Abstract][Full Text] [Related]
5. Design and synthesis of novel imidazo[4,5-b]pyridine based compounds as potent anticancer agents with CDK9 inhibitory activity.
Ghanem NM; Farouk F; George RF; Abbas SES; El-Badry OM
Bioorg Chem; 2018 Oct; 80():565-576. PubMed ID: 30025343
[TBL] [Abstract][Full Text] [Related]
6. Aminopyrazole based CDK9 PROTAC sensitizes pancreatic cancer cells to venetoclax.
King HM; Rana S; Kubica SP; Mallareddy JR; Kizhake S; Ezell EL; Zahid M; Naldrett MJ; Alvarez S; Law HC; Woods NT; Natarajan A
Bioorg Med Chem Lett; 2021 Jul; 43():128061. PubMed ID: 33895280
[TBL] [Abstract][Full Text] [Related]
7. Discovery of coumarin derivatives as potent and selective cyclin-dependent kinase 9 (CDK9) inhibitors with high antitumour activity.
Xu J; Li H; Wang X; Huang J; Li S; Liu C; Dong R; Zhu G; Duan C; Jiang F; Zhang Y; Zhu Y; Zhang T; Chen Y; Tang W; Lu T
Eur J Med Chem; 2020 Aug; 200():112424. PubMed ID: 32447197
[TBL] [Abstract][Full Text] [Related]
8. Discovery and synthesis of novel Wogonin derivatives with potent antitumor activity in vitro.
Wang J; Ge R; Qiu X; Xu X; Wei L; Li Z; Bian J
Eur J Med Chem; 2017 Nov; 140():421-434. PubMed ID: 28987604
[TBL] [Abstract][Full Text] [Related]
9. Targeted degradation of anaplastic lymphoma kinase by gold nanoparticle-based multi-headed proteolysis targeting chimeras.
Wang Y; Han L; Liu F; Yang F; Jiang X; Sun H; Feng F; Xue J; Liu W
Colloids Surf B Biointerfaces; 2020 Apr; 188():110795. PubMed ID: 31991291
[TBL] [Abstract][Full Text] [Related]
10. Discovery of IAP-recruiting BCL-X
Zhang X; He Y; Zhang P; Budamagunta V; Lv D; Thummuri D; Yang Y; Pei J; Yuan Y; Zhou D; Zheng G
Eur J Med Chem; 2020 Aug; 199():112397. PubMed ID: 32388279
[TBL] [Abstract][Full Text] [Related]
11. Lessons in PROTAC Design from Selective Degradation with a Promiscuous Warhead.
Bondeson DP; Smith BE; Burslem GM; Buhimschi AD; Hines J; Jaime-Figueroa S; Wang J; Hamman BD; Ishchenko A; Crews CM
Cell Chem Biol; 2018 Jan; 25(1):78-87.e5. PubMed ID: 29129718
[TBL] [Abstract][Full Text] [Related]
12. Discovery of selective CDK9 degraders with enhancing antiproliferative activity through PROTAC conversion.
Qiu X; Li Y; Yu B; Ren J; Huang H; Wang M; Ding H; Li Z; Wang J; Bian J
Eur J Med Chem; 2021 Feb; 211():113091. PubMed ID: 33338869
[TBL] [Abstract][Full Text] [Related]
13. Novel cyclin-dependent kinase 9 (CDK9) inhibitor with suppression of cancer stemness activity against non-small-cell lung cancer.
Wang X; Yu C; Wang C; Ma Y; Wang T; Li Y; Huang Z; Zhou M; Sun P; Zheng J; Yang S; Fan Y; Xiang R
Eur J Med Chem; 2019 Nov; 181():111535. PubMed ID: 31376566
[TBL] [Abstract][Full Text] [Related]
14. Pharmacologic targeting of the P-TEFb complex as a therapeutic strategy for chronic myeloid leukemia.
Qing Y; Wang X; Wang H; Hu P; Li H; Yu X; Zhu M; Wang Z; Zhu Y; Xu J; Guo Q; Hui H
Cell Commun Signal; 2021 Aug; 19(1):83. PubMed ID: 34372855
[TBL] [Abstract][Full Text] [Related]
15. Chemically induced degradation of CK2 by proteolysis targeting chimeras based on a ubiquitin-proteasome pathway.
Chen H; Chen F; Liu N; Wang X; Gou S
Bioorg Chem; 2018 Dec; 81():536-544. PubMed ID: 30245235
[TBL] [Abstract][Full Text] [Related]
16. Selective CDK9 degradation using a proteolysis-targeting chimera (PROTAC) strategy.
Mallareddy JR; Singh S; Boghean L; Natarajan A
Future Med Chem; 2022 Jan; 14(3):131-134. PubMed ID: 34814708
[No Abstract] [Full Text] [Related]
17. Proteolysis Targeting Chimeras (PROTACs) of Anaplastic Lymphoma Kinase (ALK).
Zhang C; Han XR; Yang X; Jiang B; Liu J; Xiong Y; Jin J
Eur J Med Chem; 2018 May; 151():304-314. PubMed ID: 29627725
[TBL] [Abstract][Full Text] [Related]
18. Discovery of a highly potent, selective and novel CDK9 inhibitor as an anticancer drug candidate.
Li Y; Guo Q; Zhang C; Huang Z; Wang T; Wang X; Wang X; Xu G; Liu Y; Yang S; Fan Y; Xiang R
Bioorg Med Chem Lett; 2017 Aug; 27(15):3231-3237. PubMed ID: 28651979
[TBL] [Abstract][Full Text] [Related]
19. Multiple myeloma: Combination therapy of BET proteolysis targeting chimeric molecule with CDK9 inhibitor.
Lim SL; Xu L; Han BC; Shyamsunder P; Chng WJ; Koeffler HP
PLoS One; 2020; 15(6):e0232068. PubMed ID: 32559187
[TBL] [Abstract][Full Text] [Related]
20. A "Click Chemistry Platform" for the Rapid Synthesis of Bispecific Molecules for Inducing Protein Degradation.
Wurz RP; Dellamaggiore K; Dou H; Javier N; Lo MC; McCarter JD; Mohl D; Sastri C; Lipford JR; Cee VJ
J Med Chem; 2018 Jan; 61(2):453-461. PubMed ID: 28378579
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]